Evidence map›Paper›PMID 34125066›Full record

ReviewCanadian Urological Association journal = Journal de l'Association des urologues du Canada2021

Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers.

Fred Saad, Sebastien J Hotte, Antonio Finelli, Shawn Malone, Tamim Niazi, Krista Noonan, Bobby Shayegan, Alan I So, Brita Danielson, Naveen S Basappa and 22 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Gender bias in shared decision-making among cancer care guidelines: A systematic review.Health expectations : an international journal of public participation in health care and health policy · 2023
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Fred SaadCentre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada.
Sebastien J HotteJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Antonio FinelliPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Shawn MaloneThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Tamim NiaziJewish General Hospital, McGill University, Montreal, QC, Canada.
Krista NoonanBC Cancer Agency, University of British Columbia, Surrey, BC, Canada.
Bobby ShayeganSt. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Alan I SoProstate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.
Brita DanielsonCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Naveen S BasappaCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Ilias CagiannosThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Christina CanilThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Guila DelouyaCentre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada.
Ricardo FernandesLondon Health Sciences Centre, Western University, London, ON, Canada.
Cristiano FerrarioJewish General Hospital, McGill University, Montreal, QC, Canada.
Geoffrey T GottoSouthern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada.
Robert J HamiltonPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Jason P IzardKingston Health Sciences Centre, Queen's University, Kingston, ON.
Anil KapoorSt. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Daniel KhalafBC Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
Michael KolinskyCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Aly-Khan LalaniJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Luke T LavalléeThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Christopher MorashThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Scott C MorganThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Michael OngThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Frédéric PouliotQuebec City University Hospital Center & Centre de Recherche of Quebec City University Hospital Center, University of Laval, QC, Canada.
Ricardo A RendonQueen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
Steven YipTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Anousheh ZardanMedical Affairs, Janssen Inc, Toronto, ON, Canada.
Laura Park-WyllieMedical Affairs, Janssen Inc, Toronto, ON, Canada.
Kim ChiBC Cancer Agency, University of British Columbia, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRapid progress in diagnostics and therapeutics for the management of prostate cancer (PCa) has created areas where high-level evidence to guide practice is lacking. The Genitourinary Research Consortium (GURC) conducted its second Canadian consensus forum to address areas of controversy in the management of PCa and provide recommendations to guide treatment.

methodsA panel of PCa specialists discussed topics related to the management of PCa. The core scientific committee finalized the design, questions, and analysis of the consensus results. Attendees then voted to indicate their management choice regarding each statement/topic. Questions for voting were adapted from the 2019 Advanced Prostate Cancer Consensus Conference. The thresholds for agreement were set at ≥75% for "consensus agreement," >50% for "near-consensus," and ≤50% for "no consensus."

resultsThe panel was comprised of 29 PCa experts, including urologists (n=12), medical oncologists (n=12), and radiation oncologists (n=5). Voting took place for 65 predetermined questions and three ad hoc questions. Consensus was reached for 34 questions, spanning a variety of areas, including biochemical recurrence, treatment of metastatic castration-sensitive PCa, management of non-metastatic and metastatic castration-resistant PCa, bone health, and molecular profiling.

conclusionsThe consensus forum identified areas of consensus or near-consensus in more than half of the questions discussed. Areas of consensus typically aligned with available evidence, and areas of variability may indicate a lack of high-quality evidence and point to future opportunities for further research and education.

Identifiers

PMID34125066
PMCPMC8525526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.